Fundamental Data for ENDP

Endo Pharmaceuticals Holdings Inc., through its wholly owned subsidiaries, Endo Pharmaceuticals Inc. and Endo Inc., is engaged in the research, development, sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain.

# Employees: 1216

Address: 100 Endo Boulevard,Chadds Ford,PA,USA

Phone: 610-558-9800

Fax: 610-558-8979

Website: www.endo.com

Email: IR@Endo.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Roger H. Kimmel (Chmn.; Dir.)

Peter A. Lankau (Presi.; C.E.O.)

Charles A. Rowland Jr. (Exec. V.P.; C.F.O.; Treas.)

Caroline B. Manogue (Exec. V.P.; Chief Legal Off.; Sec.)

Joyce N. Laviscount (Chief Acctg. Off.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/19/2010

Mean EPS (Next Qtr): $0.68

Mean EPS (Year): $2.71

Mean Estimate(Long Term): $10.20

P/E Ratio(Based on EPS estimate): 8.190

Number of Estimates: 22

Shares Performance

Period	ENDP	Compare to S&P
YTD	-14.22 %	-29.01 %
4 Weeks	-4.60 %	-5.63 %
12 Weeks	-2.37 %	-7.96 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1304116

Shares Outstanding: 117M

Market Cap: $2.60B

52 Week High: $26.08

52 Week Low: $15.83

P/E Ratio: 8.250

PEG Ratio: 0.800

Split: On 1/1/1990 ENDP split by factor of 0.670

Earnings Performance

EPS Growth in Last Quarter: -13.70 %

EPS Growth in Last Year: 3.28 %

Sales Growth in Last Quarter: -3.24 %

Sales Growth in Last Quarter: 13.97 %

Financials

Qtr Book Value: $1.94

Cash Flow/Share: $7.62

Change in Payout Ratio: 0.000

Price/Sales: 1.840